

Please amend claims 15, 16, 24, 26-32, 35, 40, 41 and 54 to read as follows:

F¹ 15. (TWICE AMENDED) A medicament comprising a therapeutic unit of Colostrinin in isolated form for use in the treatment of dementia and/or neurodegenerative diseases in humans.

16. (TWICE AMENDED) A medicament comprising a therapeutic unit of Colostrinin in isolated form for use in the treatment of Alzheimer's disease in humans.

F² 24. (THRICE AMENDED) A method of treating a human patient afflicted with dementia and/or a neurodegenerative disease, the method comprising administering a composition comprising a therapeutic unit of Colostrinin in isolated form to the human patient about one or two times per day for a predetermined period of time.

F³ 26. (THRICE AMENDED) The method according to claim 24 wherein the Colostrinin is non-ovine Colostrinin.

F⁴ 27. (TWICE AMENDED) A method according to claim 26, wherein said therapeutic unit of Colostrinin is in the range of about 25 to 1000 micrograms.

F⁵

28. (AMENDED) The method according to claim 24 wherein the therapeutic unit of Colostrinin in isolated form is administered to the patient about one or two times each day for a first period of time, followed by a second period of time when no Colostrinin is administered.

29. (AMENDED) The method according to claim 28 wherein the first period of time is in the range of about 2 to 4 weeks, and the second period of time is in the range of about 2 to 5 weeks.

F⁶

30. (TWICE AMENDED) The method according to claim 28 wherein a cycle of administering Colostrinin in isolated form for a first period of time followed by a second period of time when Colostrinin is administered is repeated at least once.

F⁷

31. (THRICE AMENDED) A pharmaceutical composition for oral administration to a human patient in the treatment of dementia and/or a neurodegenerative disorder, the pharmaceutical composition comprising a therapeutic unit of Colostrinin in isolated form in combination with a physiologically acceptable carrier.

F⁸

32. (AMENDED) The pharmaceutical composition according to claim 31 wherein the Colostrinin is non-ovine Colostrinin.

F9

35. (FOUR TIMES AMENDED) The pharmaceutical composition according to claim 31 in the form of a tablet, lozenge or gel.

F10

40. (TWICE AMENDED) A dietary supplement for humans comprising a therapeutic unit of Colostrinin in isolated form.

F11

41. (TWICE AMENDED) A dietary supplement for humans comprising an orally ingestible combination of a therapeutic unit of Colostrinin in an isolated form in combination with a physiologically acceptable carrier.

F12

54. (THRICE AMENDED) A pharmaceutical composition for oral administration to a human patient comprising a nonapeptide having the amino acid sequence Val-Glu-Ser-Tyr-Val-Pro-Leu-Phe-Pro (SEQ ID NO:1) in isolated form in combination with a physiologically acceptable carrier.

REMARKS

By this Amendment, claims 3-7, 13, 14, 17, 33, 34, 36, 46, 47, 53 and 55-57 have been canceled and claims 15, 16, 24, 26-32, 35, 40, 41 and 54 have been amended. Accordingly, claims 15, 16, 24, 26-32, 35, 40, 41 and 54 are presently pending in the application. A version showing the changes made to claims 15, 16, 24, 26-32, 35, 40, 41 and 54 is appended as "Attachment A."